印度的学名药市场评估:各用途，各类型，不同品牌，各给药途径，各流通管道，各地区，机会，预测(2018年度～2032年度)

印度仿製药市场规模预计将从 2024 财年的 137.1 亿美元增至 2032 财年的 259.4 亿美元，预计 2025 财年至 2032 财年的复合年增长率为 8.29%。市场成长得益于政府推出的支持性政策和措施、慢性病盛行率的上升以及主要市场参与者增加投资的支持。人们对仿製药相关各种益处的认识不断提高，也推动了印度对仿製药的需求。仿製药透过确保具有成本效益的治疗来帮助满足国家的医疗保健需求。

市场成长也受到该国市场领导者推出新药的支持。 2023年1月，太阳製药工业有限公司在印度推出了辉瑞乳癌药物palbociclib的仿製药。该公司的印度专利到期后，仿製药就有可能进入市场。该新药的上市将确保该药物在印度的供应，提高患者的便利性，并为对抗印度最常见的癌症之一乳癌做出贡献。根据全球癌症观察站 (GCO) 估计，2022 年印度将有约 98,337 名女性死于乳癌。

主要市场参与者也积极投资复杂仿製药的开发，并且越来越注重研发活动。对仿製药的严格监管可确保患者能够获得并维持有效的治疗解决方案，这对于对抗需要频繁用药的慢性和终身疾病至关重要。

慢性病患者增加带动市场需求

该国糖尿病、癌症、神经血管疾病和心血管疾病等各种慢性疾病的盛行率不断上升，正在为市场创造利润丰厚的成长机会。根据世界卫生组织（WHO）估计，印度18岁以上的人中约有7,700万人患有第2型糖尿病，其中2,500万人处于罹患糖尿病的高风险之中。越来越多的此类疾病患者，以及生活方式的改变和人口老化，需要医疗保健专业人员和患者都青睐的具有成本效益的长期药物，以支持市场成长。

政府加大力度支持市场扩张

越来越多地推出支持性政策和措施来促进製药业的研发活动，正在扩大印度的仿製药市场规模。 2023年9月，国家医药医疗技术研发创新政策出台，支持全球製药业转型为高价值、高产量企业。该政策旨在激励国内外企业增加某些高价值产品的生产和投资，例如复杂仿製药、专利到期药物和生物製药。此类举措预计将支持复杂仿製药的开发并对市场扩张产生积极影响。

心血管应用占主要市占率

印度心血管疾病患者数量不断增加，这推动了印度仿製药市场的需求。根据2022年2月发表在《临床流行病学与全球健康》的一篇论文，印度45岁以上成年人自报的心血管疾病盛行率为29.4%。该国心血管疾病患者数量的增加可归因于缺乏运动、高胆固醇和糖尿病。这种增长增加了对心血管治疗仿製药的需求。由于其成本效益，仿製药替代对于患者和卫生系统都具有潜在的重要意义。此外，这种替代提高了药品支出的价值。

本报告针对印度仿製药市场进行研究和分析，提供市场规模和预测、市场动态、主要参与者的现状和前景等。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 印度的学名药市场预测(2018年度～2032年度)

• 市场规模的分析与预测
  • 金额
  • 数量
• 市场占有率分析与预测
  • 各用途
  • 各类型
  • 不同品牌
  • 各给药途径
  • 各流通管道
  • 各地区
  • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2024年度)
• 市场地图分析(2024年度)
  • 各用途
  • 各类型
  • 不同品牌
  • 各给药途径
  • 各流通管道
  • 各地区

第5章 供需分析

第6章 进口和出口的分析

第7章 价值链分析

第8章 波特的五力分析

第9章 大环境分析

第10章 价格分析

第11章 市场动态

• 推动市场要素
• 市场课题

第12章 市场趋势与发展

第13章 法规结构和革新

• 生物有效性/生物学的同等性实验
• 法规当局的认证

第14章 专利的有效期限

第15章 案例研究

第16章 竞争情形

• 市场领导者前五名公司的竞争矩阵
• 前五名公司的SWOT分析
• 主要企业前十大企业的形势
  • Aurobindo Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Teva Pharmaceuticals Industries Ltd.
  • Lupin Ltd.
  • Zydus Group
  • Novartis AG
  • Fresenius Kabi India Pvt. Ltd.
  • Viatris Inc.

第17章 策略性推荐

第18章 本公司相关资料，免责声明

India generic drugs market is projected to witness a CAGR of 8.29% during the forecast period FY2025-FY2032, growing from USD 13.71 billion in FY2024 to USD 25.94 billion in FY2032. The market's growth is supported by the introduction of supportive government policies and initiatives, the increasing prevalence of chronic diseases, and rising investments by the key market players. The growing awareness about the various advantages associated with generic drugs is also propelling the demand for generic drugs in India. Generic drugs aid in addressing the healthcare requirements of the country's population by ensuring the availability of cost-effective treatments.

The growth of the market is also supported by novel drug launches by the key players of the market in the country. In January 2023, Sun Pharmaceutical Industries Ltd. launched the generic version of palbociclib, Pfizer Inc.'s breast cancer medicine, in India. The entry of the generic version of the drug was possible after the expiration of the company's Indian patent on the product. This launch ensured the affordability of the drug in the country, aiding in improving patient accessibility and combating breast cancer, which is one of the most common forms of cancer in India. As per the estimates of the Global Cancer Observatory (GCO), India had approximately 98,337 female deaths related to breast cancer in 2022.

Additionally, the key market players are actively investing towards the development of complex generic drugs and increasingly focusing on research and development activities. The stringent regulations for generic drugs ensure the availability of effective therapeutic solutions while maintaining their affordability, which is essential for combating chronic and lifelong diseases in which the patient requires frequent doses of medications.

Rising Cases of Chronic Diseases Boosts Market Demand

The increasing incidence of various chronic diseases in the country, including diabetes, cancer, neurovascular diseases, and cardiovascular diseases, among others, are providing lucrative growth opportunities to the market. The World Health Organization (WHO) estimates that approximately 77 million individuals above the age of 18 in India suffer from type 2 diabetes, and 25 million are at a greater risk of developing diabetes. The rising cases of such diseases, coupled with changing lifestyles and the expansion of the aging population, are propelling the requirement for long-term medications that are cost-effective and are preferred by both healthcare providers and patients, supporting the India generic drugs market growth.

Increasing Government Initiatives Support Market Expansion

The increasing launch of supportive policies and initiatives to promote research and development activities in the pharmaceutical sector is boosting India's generic drugs market size. In September 2023, the National Policy on Research and Development and Innovation in Pharma-MedTech Sector was launched to support the country's transformation into a high-value and volume player in the global pharmaceuticals industry. The policy aims to incentivize the domestic and global players to enhance production and investments in specific high-value products, including complex generic drugs, drugs nearing patent expiration, and biopharmaceuticals, among others. Such initiatives are expected to support the development of complex generic drugs and positively influence the market's expansion.

Cardiovascular Applications Hold Significant Market Share

The rising cases of cardiovascular diseases in the country are bolstering the India generic drugs market demand. According to an article published in Clinical Epidemiology and Global Health in February 2022, the self-reported prevalence of cardiovascular diseases in India was 29.4% for adults aged 45 and above. The increasing number of cases of cardiovascular diseases in the country can be attributed to a lack of physical activity, high cholesterol, and diabetes. This increase is propelling the requirement for generic versions of cardiovascular drugs as the generic substitutions are potentially important for both patients and the healthcare system due to their cost-effectiveness. Furthermore, the substitution also improves the value of pharmaceutical spending.

Meanwhile, diabetology is expected to witness significant growth in the coming years. The rising cases of diabetes in India can be attributed to the profound lifestyle and environmental changes witnessed by the population. These changes, including rising per capita spending, industrialization, booming culture of eating out, and migration to urban cities, are contributing to the increasing prevalence of diabetes.

Retail Pharmacies Account for Major Market Share

The strong presence of retail pharmacies in the country and the pharmacist's personalized consultation and recommendations are bolstering the segment's expansion. Additionally, these pharmacies provide a wide range of healthcare products and drugs at one location, which in turn enhances consumer convenience. Various retail pharmacy chains are rapidly growing in the country by providing such advantages to customers. For instance, in September 2022, Apollo Pharmacy announced the opening of its 5000th outlet in India.

Meanwhile, online pharmacies are expected to witness significant growth over the forecast period. This growth can be attributed to the convenience, accessibility, and value-added services online pharmacies provide. They eliminate the requirement for physically visiting the store to pick up the medications, while providing overnight shipping and delivery, aiding patients in effectively managing their diseases.

Future Market Scenario (FY2025-FY2032F)

According to the India generic drugs market analysis, the market is expected to witness significant growth in the coming years owing to the rapid expansion of the healthcare sector, increasing prevalence of chronic diseases and disorders, and rising requirements for affordable healthcare solutions. As per the statistical analysis of incidence rates of cancer published in the Indian Journal of Public Health, the burden of cancer is estimated to rise to 2.98 million by 2025 in India. The ongoing investments in research and development and manufacturing activities and the introduction of supportive government policies are also expected to support the growth of the market over the forecast period. Additionally, the increasing focus of various key market players towards the introduction of generic drugs in the country is also supporting the market's expansion. Furthermore, the introduction of various technologies, including 3-D printing, to support the manufacturing of generic drugs is also propelling the share of generic medicines in the country's pharma industry.

Key Players Landscape and Outlook

The growth of the India generic drugs market is supported by the increasing investments by the key players of the market towards the launch of various generic drugs in India. In March 2024, the Zydus Group launched IBYRA, the generic version of Olaparib, which is a PARP inhibitor in India. The drug targets genetic mutations that are present in different cancer types, allowing for more effective and tailored treatment approaches. Cancer patients who have been diagnosed with BRACA and HRD-positive mutations are administered PARP inhibitors to delay the progression of the diseases. To ensure that the correct patient groups have access to IBYRA, Zydus collaborated with MedGenome Inc. for comprehensive HRD testing.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Generic Drugs Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Application
    • 4.2.1.1. Neurovascular
    • 4.2.1.2. Cardiovascular
    • 4.2.1.3. Dermatology
    • 4.2.1.4. Oncology
    • 4.2.1.5. Diabetology
    • 4.2.1.6. Respiratory
    • 4.2.1.7. Others
  • 4.2.2. By Type
    • 4.2.2.1. Biosimilar Generics
    • 4.2.2.2. Small Molecule Generics
  • 4.2.3. By Brand
    • 4.2.3.1. Branded Generic
    • 4.2.3.2. Pure Generic
  • 4.2.4. By Route of Administration
    • 4.2.4.1. Oral
    • 4.2.4.2. Injectable
    • 4.2.4.3. Topical
    • 4.2.4.4. Others
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacy
    • 4.2.5.2. Retail Pharmacy
    • 4.2.5.3. Online Pharmacy
  • 4.2.6. By Region
    • 4.2.6.1. North
    • 4.2.6.2. East
    • 4.2.6.3. West and Central
    • 4.2.6.4. South
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Application
  • 4.3.2. By Type
  • 4.3.3. By Brand
  • 4.3.4. By Route of Administration
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Bioavailability/Bioequivalence Studies
• 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Aurobindo Pharmaceuticals
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Sun Pharmaceutical Industries Ltd.
  • 16.3.3. Cipla Ltd.
  • 16.3.4. Dr. Reddy's Laboratories
  • 16.3.5. Teva Pharmaceuticals Industries Ltd.
  • 16.3.6. Lupin Ltd.
  • 16.3.7. Zydus Group
  • 16.3.8. Novartis AG
  • 16.3.9. Fresenius Kabi India Pvt. Ltd.
  • 16.3.10. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Generic Drugs Market, By Value, In USD Billion, FY2018-FY2032F
• Figure 2. India Generic Drugs Market, By Volume, In Number of Prescriptions, FY2018-FY2032F
• Figure 3. India Generic Drugs Market Share (%), By Application, FY2018-FY2032F
• Figure 4. India Generic Drugs Market Share (%), By Type, FY2018-FY2032F
• Figure 5. India Generic Drugs Market Share (%), By Brand, FY2018-FY2032F
• Figure 6. India Generic Drugs Market Share (%), By Route of Administration, FY2018-FY2032F
• Figure 7. India Generic Drugs Market Share (%), By Distribution Channel, FY2018-FY2032F
• Figure 8. India Generic Drugs Market Share (%), By Region, FY2018-FY2032F
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 11. By Brand Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024